Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.
Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E. Mansier O, et al. Among authors: adiko d. Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. Am J Hematol. 2018. PMID: 29266414 Free article. No abstract available.
Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy: results from the multicenter FOX study of 177 patients in France.
Rey J, Viallard JF, Keddad K, Smith J, Wilde P, Kiladjian JJ; FOX study investigators. Rey J, et al. Eur J Haematol. 2014 Feb;92(2):127-36. doi: 10.1111/ejh.12210. Epub 2013 Nov 25. Eur J Haematol. 2014. PMID: 24118452 Free PMC article. Clinical Trial.
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.
Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX. Etienne G, et al. Among authors: adiko d. Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20. Haematologica. 2014. PMID: 24362549 Free PMC article.
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Etienne G, Faberes C, Bauduer F, Adiko D, Lifermann F, Dagada C, Lenoir C, Schmitt A, Klein E, Fort MP, Bijou F, Turcq B, Robbesyn F, Durrieu F, Versmée L, Madene S, Moldovan M, Katsahian S, Charles-Nelson A, Lascaux A, Mahon FX, Dulucq S. Etienne G, et al. Among authors: adiko d. Cancer Med. 2021 Jun;10(11):3635-3645. doi: 10.1002/cam4.3921. Epub 2021 May 14. Cancer Med. 2021. PMID: 33988316 Free PMC article.
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Etienne G, Dulucq S, Bauduer F, Adiko D, Lifermann F, Dagada C, Lenoir C, Schmitt A, Klein E, Madene S, Fort MP, Bijou F, Moldovan M, Turcq B, Robbesyn F, Durrieu F, Versmée L, Katsahian S, Faberes C, Lascaux A, Mahon FX. Etienne G, et al. Among authors: adiko d. Cancers (Basel). 2020 Sep 4;12(9):2521. doi: 10.3390/cancers12092521. Cancers (Basel). 2020. PMID: 32899879 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 31857362
Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk.
Corre J, Montes L, Martin E, Perrot A, Caillot D, Leleu X, Belhadj K, Facon T, Hulin C, Mohty M, Fontan J, Macro M, Brechignac S, Jaccard A, Stoppa AM, Orsini-Piocelle F, Adiko D, Voillat L, Keddar F, Barry M, Demarquette H, Certain MN, Plantier I, Roussel M, Hébraud B, Filleron T, Attal M, Avet-Loiseau H. Corre J, et al. Among authors: adiko d. Haematologica. 2020 Sep 1;105(9):e480-483. doi: 10.3324/haematol.2019.236588. Haematologica. 2020. PMID: 33054068 Free PMC article. No abstract available.
Final results on effectiveness and safety of Ibrutinib in patients with chronic lymphocytic leukemia from the non-interventional FIRE study.
Dartigeas C, Quinquenel A, Ysebaert L, Dilhuydy MS, Anglaret B, Slama B, Le Du K, Tardy S, Tchernonog E, Orfeuvre H, Voillat L, Guidez S, Malfuson JV, Dupuis S, Deslandes M, Feugier P, Leblond V; FIRE Investigators Group. Dartigeas C, et al. Ann Hematol. 2024 Mar 6. doi: 10.1007/s00277-024-05666-3. Online ahead of print. Ann Hematol. 2024. PMID: 38443660
12 results